DEF 14A: Forte Biosciences Seeks Stockholder Approval for Amended Equity Incentive Plan

Forte Biosciences is asking stockholders to approve an amended and restated 2021 Equity Incentive Plan to attract and retain talent.

Summary

• Forte Biosciences is holding a Special Meeting of Stockholders on January 24, 2025, to vote on the approval of an amended and restated 2021 Equity Incentive Plan.
• The Board of Directors recommends voting FOR the approval of the amended plan.
• The amended plan includes an additional 3,000,000 shares of common stock for awards to service providers.
• Shares tendered or withheld for payment of an exercise price or for tax withholding obligations with respect to awards granted under the Tocagen, Inc. 2009 Equity Incentive Plan, the Tocagen, Inc. 2017 Equity Incentive Plan, and the Forte Biosciences Inc. 2018 Equity Incentive Plan will not become available for future grant under the A&R 2021 Plan.
• As of December 30, 2024, there were 6,393,323 shares of Common Stock outstanding.
• The Board believes the ability to grant equity-based awards is crucial for attracting, retaining, and motivating key talent.
• The company anticipates the requested shares will be enough to meet their expected needs through approximately 2026.
• As of December 31, 2024, 127,508 shares remained available for issuance under the Current Plan.
• The 233,238 shares subject to outstanding equity awards under all of our Prior Plans and the Current Plan as of December 31, 2024 represent approximately 3.6% of our outstanding Shares as of December 31, 2024.
• In 2023, equity awards covered 56,200 shares, and in 2024, they covered 120,800 shares.
• The annual burn rate was 4.5% for fiscal year 2023 and 4.1% for fiscal year 2024.
• The amended plan includes compensation and governance best practices, such as independent administration, no repricing without stockholder approval, reasonable limits on non-employee director compensation, no dividends on unvested awards, and no single-trigger vesting acceleration upon a change in control.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The overall sentiment is moderately positive as the company is taking steps to ensure it can attract and retain talent, which is crucial for future growth.

Positives

• The amended plan aims to strengthen the company's ability to attract, retain, and motivate employees, officers, non-employee directors, and certain other service providers.
• The plan includes compensation and governance best practices to protect stockholders' interests.
• The plan does not contain an annual evergreen provision to automatically increase the number of shares available for issuance each year.
• Shares used to pay the exercise price of an award or to satisfy the tax liabilities or withholdings related to an award will not become available for future grant or sale under the Plan.
• The plan sets reasonable limits as to the total compensation that non-employee directors may receive during each fiscal year.
• The plan prohibits the payment of any dividends or other distributions with respect to Shares underlying awards that are not fully vested with the underlying Shares issued.
• The plan provides for no automatic vesting of awards upon a change in control unless the award is not assumed or substituted.
• Awards under the plan generally may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner, unless otherwise approved by the administrator.
• The plan does not provide for any tax gross-ups.

Negatives

• If stockholders do not approve the amended plan, the company may be limited in its ability to attract, recruit, and retain employees and other service providers.
• The approval of the amended plan will result in further dilution of existing stockholders' equity.

Risks

• Failure to secure stockholder approval for the amended equity incentive plan could hinder the company's ability to attract and retain talent.
• The additional shares authorized under the amended plan will dilute existing stockholders' ownership.

Future Outlook

The company anticipates the requested shares will be enough to meet their expected needs through approximately 2026.

Management Comments

• On behalf of our Board of Directors (the Board), we would like to express our appreciation for your continued support of and interest in Forte.
• The Board recommends that our stockholders approve the A&R 2021 Plan because it believes our ability to grant equity-based awards is crucial in allowing the company to effectively compete for and appropriately motivate and reward key talent.
• It is in the long-term interest of both the company and its stockholders to strengthen the companys ability to attract, retain and motivate employees, officers, nonemployee directors and certain other service providers, and to provide additional incentive for those persons through stock ownership and other incentives to improve financial performance, increase profits and strengthen the mutuality of interest between those persons and the companys stockholders.

Industry Context

Equity incentive plans are a common tool used by companies, especially in the biotech industry, to attract and retain talent by aligning employee interests with those of the shareholders.

Comparison to Industry Standards

• The document mentions retaining Vareo Advisors, an independent compensation consultant, to review the Company's employee share usage, dilution to employees, equity overhang, and annual equity burn rate, as well as provide a market analysis against the Company's peer group.
• This suggests that Forte Biosciences is benchmarking its equity compensation practices against industry standards and peer companies to ensure competitiveness.
• Without specific details on the peer group and the consultant's findings, it's difficult to provide a more detailed comparison to industry standards.
• However, the document's emphasis on governance best practices and limiting dilution aligns with general trends in executive compensation.

Stakeholder Impact

• Approval of the amended equity incentive plan could positively impact employees by providing them with equity-based compensation.
• Approval of the amended equity incentive plan could positively impact shareholders by aligning employee interests with those of the shareholders.
• Failure to approve the amended equity incentive plan could negatively impact employees by limiting the company's ability to offer competitive compensation packages.
• Failure to approve the amended equity incentive plan could negatively impact shareholders by hindering the company's ability to attract and retain talent.

Next Steps

• Stockholders need to vote on the proposal to approve the amended and restated 2021 Equity Incentive Plan.
• The company will announce the voting results on a Current Report on Form 8-K that it will file with the U.S. Securities and Exchange Commission, or SEC, within four business days after the meeting.

Key Dates

Keywords

Equity Incentive Plan, Stockholders, Compensation, Shares, Awards, Forte Biosciences